A Screening Program for Anti‐DR Typing Reagents

Vassalli, Pierre; Jeannet, M; Moerloose, P de; Chardonnens, X

doi:10.1111/j.1399-0039.1979.tb01142.x

Cited by 7 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By using quantitative microabsorption, Pellegrino et al (1978) have found that B lymphocytes express more HLA-AB antigens than T lymphocytes, although this difference was not found to be accompanied by greater susceptibility of the B cells to complement mediated lysis by HLA-AB antisera. Others, however, (Richiardi et al 1977, Vassalli et al 1979) have reported on cytotoxic sera reacting only with B cells, and not with T cells, with clearcut HLA-A or -B specificity. The present report demonstrates the possibility of B cell specific antisera even without discernible HLA-AB specificity giving occasional strong reactions which in fact are caused by HLA-AB antibodies, but mediated through synergistic action with HLA-DR components.…”

Section: Discussionmentioning

confidence: 97%

“…Likewise, synergism is also a factor of significance in HLA-DR serology which may explain unusual and actually "falsely positive" reactions. It is a common experience that HLA-DR test sera are often "contaminated" with HLA-ABC antibodies (Baricordi et al 1979, Vassalli et al 1979) and need absorption with platelets before use. Alternativcly, sera with weak HLA-ABC antibodies in addition to the HLA-DR component may be used without absorption if diluted properly out of detectable reactivity against T cells.…”

Section: Discussionmentioning

confidence: 99%

“…Synergism between mixtures of HLA-DR antibodies of different specificity in antisera might be expected to be of equal significance in HLA-DR serology; and, in particular, synergistic action between HLA-DR antibodies and HLA-ABC antibodies might be of special importance because of the frequent simultaneous occurrence of these two groups of antibodies in HLA-DR specific antisera (Baricordiet al 1977, Vassalli et al 1979.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Synergism and Gene Dose Effect in HLA‐DR Serology

Madsen

1981

Tissue Antigens

View full text Add to dashboard Cite

By mixing HLA‐DR antisera of different specificities and testing them against B lymphocytes carrying the corresponding antigens, a synergistic action of HLA‐DR antibodies was revealed. Furthermore, it was demonstrated that HLA‐DR and HLA‐ABC antibodies may act synergistically against appropriate B cells. HLA‐DR homozygous B lymphocytes were found to react more strongly with HLA‐DR specific antisera than heterozygous cells, thus revealing a gene dose effect in HLA‐DR serology. ABO antibodies were found not to react against B lymphocytes, either alone nor in concert with HLA‐DR antisera. The practical implications of synergism and gene dose effect in HLA‐DR serology are discussed.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Synergism and Gene Dose Effect in HLA‐DR Serology

Madsen

1981

Tissue Antigens

View full text Add to dashboard Cite

show abstract

“…In contrast, sera devoid of HLA-A,-B,-C antibodies are rarely strongly anti HLA-DR reactive (Baricordi et 0001-2815/82/060033-14 $ 02.5010 @ 1982Munksgaard, Copenhagen al. 1977, Moerloose et al 1977, Vassalli et al 1979, Muller et al 1980. This fact has 2 important implications.…”

mentioning

confidence: 99%

“…This fact has 2 important implications. Firstly, most sera containing HLA-DR antibodies have to be extensively absorbed with relevant platelets to remove HLA-A,-B,-C antibodies, and this in turn tends to weaken the anti HLA-DR reactivity, probably by non-specific absorption to the platelets (Vassalli et al 1979). Secondly, valuable HLA-DR antibodies may be overlooked in the screening procedure because of the simultaneous occurrence of HLA-A,-B,-C antibodies.…”

mentioning

confidence: 99%

Planned immunization of human volunteers with HLA‐DR incompatible lymphocytes

et al. 1982

View full text Add to dashboard Cite

Aiming at the production of anti HLA-DR test sera, eight healthy human volunteers were immunized by repeated intradermal injections of lymphocytes which were selected to be incompatible for one HLA-DR antigen, and matched as well as possible for HLA-A,-B,-C antigens. One out of 3 recipients immunized exclusively against HLA-DR produced lyrnphocytotoxic HLA-DR antibodies. The remaining 5 recipients were immunized against 1 or more HLA-A,-B,-C antigens in addition to one HLA-DR antigen. After 3 immunizations, 3 of these reacted with strong HLA-A or -B antibody production; however, only one showed a parallel anti HLA-DR antibody response detectable by complement dependent lymphocytotoxicity.Testing of the recipient sera in the antibody dependent cell-mediated cytotoxicity (ADCC) assay revealed that 6 of the 8 recipients did react early to the immunizations with HLA specific antibody production. However, in spite of repeated booster injections it was not possible to obtain more than the above-mentioned 2 sera with HLA-DR antibodies strong enough to react in the lymphocytotoxicity rnicrotechique.

show abstract

Evaluation of the humoral response of glioma patients to a possible common tumor‐associated antigen(S)

Martin-Achard

Diserens

Tribolet

et al. 1980

Intl Journal of Cancer

View full text Add to dashboard Cite

Cytotoxic antibodies against glioblastoma-associated antigen(s) have been sought for in glioma patient sera. Complement-dependent cytotoxicity (CDC) I and antibody-dependent cell-mediated cytotoxicity (ADCC) assays were used to test sera from 80 patients using 51 Cr labelled target cells derived from eight different glioblastoma lines. As more positive sera were detected with ADCC than with CDC, ADCC assay was used for the remainder of the study. Cytotoxic antibodies were detected in the sera from 8 of 80 glioma patients (10%) by CDC and in 20 of 143 (14%) by ADCC. Fourteen percent of 27 meningioma patients and 16% of 25 normal donors used as controls were found to react in ADCC against the same glioblastoma cell lines. The positive serum samples showed extensive cross-reactions with the different glioblastoma cells, but the pattern of reactivity was different for each serum tested. The antibodies detected did not seem to be directed against tumor-associated antigen(s), since the positive sera were found to have a similar ADCC reactivity against unrelated tumor cells and normal fibroblasts. Moreover, their antiglioma reactivity was absorbed by cells of unrelated tumors and by normal platelets. These results do not support previous reports of specific humoral responses in glioma patients against common tumor-associated antigen(s).

show abstract

A Screening Program for Anti‐DR Typing Reagents

Cited by 7 publications

References 7 publications

Synergism and Gene Dose Effect in HLA‐DR Serology

Synergism and Gene Dose Effect in HLA‐DR Serology

Planned immunization of human volunteers with HLA‐DR incompatible lymphocytes

Evaluation of the humoral response of glioma patients to a possible common tumor‐associated antigen(S)

Contact Info

Product

Resources

About